Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.

Autor: Pilco Teran M; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain. melipilter@gmail.com., Merino Ribas A; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Martin Alemany N; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Barros Freiria X; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Rubio Casadevall J; Clinical Oncology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Pérez Bueno F; Pathological Anatomy Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., García Méndez I; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Castillo Devia M; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Noboa Paez C; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Torguet Escuder P; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain., Calabia Martínez J; Nephrology Department, Hospital Universitari de Girona Doctor Josep Trueta, Girona, Spain.
Jazyk: angličtina
Zdroj: Investigational new drugs [Invest New Drugs] 2021 Feb; Vol. 39 (1), pp. 237-239. Date of Electronic Publication: 2020 Jul 09.
DOI: 10.1007/s10637-020-00973-8
Abstrakt: Few cases of immunoallergic tubulointerstitial nephritis associated with tyrosine kinase inhibitors have been described. We describe the first report case associated with vandetanib, a tyrosine kinase inhibitor indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (CMT) in patients with locally advanced or metastatic non-resectable disease.
Databáze: MEDLINE
Externí odkaz: